{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:45:28Z","timestamp":1787319928581,"version":"build-2736575974"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1467,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the cardiac deposition of insoluble amyloid fibrils formed by misfolded transthyretin proteins and is associated with various cardiac symptoms, such as progressive heart failure, conduction disturbance, and arrhythmia. The implementation of 99mtechnetium (99mTc)-labelled bone radiotracer scintigraphy for diagnosing ATTR-CM has enabled accurate diagnosis of the disease with high sensitivity and specificity and positioned this diagnostic modality as an integral part of disease diagnostic algorithms. In 2020, 99mTc-pyrophosphate scintigraphy received exceptional approval for Japanese national health insurance reimbursement as a diagnostic method of ATTR-CM. Nevertheless, the utility of 99mTc-labelled bone radiotracer scintigraphy and the importance of an early diagnosis of suspected ATTR-CM using this technique have yet to be internalized as common practice by general cardiologists, and guidance on daily clinical scenarios to consider this technique for a diagnosis of suspected ATTR-CM is warranted. In this review, we discuss the utility of 99mTc-labelled bone radiotracer scintigraphy for the early diagnosis of ATTR-CM based on published literature and the outcomes of an advisory board meeting. This review also discusses clinical scenarios that could support early diagnosis of suspected ATTR-CM as well as common pitfalls, correct implementation, and future perspectives of 99mTc-labelled bone radiotracer scintigraphy in daily clinical practice. The clinical scenarios to consider 99mTc-labelled bone radiotracer scintigraphy in daily practice may include, but are not limited to, patients with a family history of the hereditary type of disease; elderly patients (aged \u226560 years) with unexplained cardiac findings (e.g. cardiac hypertrophy associated with abnormalities on an electrocardiogram, heart failure with preserved ejection fraction associated with unexplained left ventricular hypertrophy, and heart failure with reduced ejection fraction associated with atrial fibrillation and left ventricular hypertrophy); and patients with cardiac hypertrophy associated with diastolic dysfunction, right ventricular\/interatrial septum\/valve thickness, left ventricular sparkling, or apical sparing. Cardiac hypertrophy and persistent elevation in cardiac troponin in elderly patients are also suggestive of ATTR-CM. 99mTc-labelled bone radiotracer scintigraphy is also recommended in patients with characteristic cardiac magnetic resonance findings (e.g. diffuse subendocardial late gadolinium enhancement patterns, native T1 increase, and increase in extracellular volume) or patients with cardiac hypertrophy and bilateral carpal tunnel syndrome.<\/jats:p>","DOI":"10.1002\/ehf2.13693","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T03:28:38Z","timestamp":1638156518000},"page":"251-262","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["99mTechnetium-Pyrophosphate Scintigraphy: A Practical Guide for Early Diagnosis of Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"9","author":[{"given":"Nobuhiro","family":"Tahara","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine , 67 Asahi-machi, Kurume, 830-0001 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center , Suita, Osaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medical Sciences, Kumamoto University , Kumamoto ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kitano","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hahn-Ey","family":"Lee","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Russo","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University , Kochi ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"2026012114184841300_ehf213693-bib-0001","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"2026012114184841300_ehf213693-bib-0002","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0003","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0004","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"2026012114184841300_ehf213693-bib-0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2026012114184841300_ehf213693-bib-0006","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"2026012114184841300_ehf213693-bib-0007","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2013evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012114184841300_ehf213693-bib-0009","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","article-title":"Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner","volume":"21","author":"Gertz","year":"2020","journal-title":"BMC Fam Pract"},{"key":"2026012114184841300_ehf213693-bib-0010","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0011","volume-title":"Notification of approval of 99mTc-PYP scintigraphy for the diagnosis of transthyretin cardiac amyloidosis (10 November 2020, website in Japanese)","author":"Japanese Circulation Society"},{"key":"2026012114184841300_ehf213693-bib-0012","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0014","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0016","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","article-title":"Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness","volume":"37","author":"Damy","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2021.04.023","article-title":"Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a tertiary referral centre in Tuscany","volume":"335","author":"Zampieri","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0018","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40119-019-00160-8","article-title":"Diagnosis of amyloidosis: a survey of current awareness and clinical challenges among cardiologists in Switzerland","volume":"9","author":"Mircsof","year":"2020","journal-title":"Cardiol Ther"},{"key":"2026012114184841300_ehf213693-bib-0019","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1007\/s12350-016-0478-3","article-title":"National patterns in imaging utilization for diagnosis of cardiac amyloidosis: a focus on Tc99m-pyrophosphate scintigraphy","volume":"24","author":"Harb","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","article-title":"Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm","volume":"13","author":"Sekijima","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"2026012114184841300_ehf213693-bib-0021","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0022","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cardfail.2017.12.005","article-title":"Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis","volume":"24","author":"Papoutsidakis","year":"2018","journal-title":"J Card Fail"},{"key":"2026012114184841300_ehf213693-bib-0023","doi-asserted-by":"crossref","first-page":"101634","DOI":"10.1016\/j.legalmed.2019.101634","article-title":"Wild-type ATTR amyloidosis may be associated with unexpected death among the elderly","volume":"41","author":"Shiozaki","year":"2019","journal-title":"Leg Med (Tokyo)"},{"key":"2026012114184841300_ehf213693-bib-0024","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","article-title":"Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study","volume":"24","author":"Ueda","year":"2011","journal-title":"Mod Pathol"},{"key":"2026012114184841300_ehf213693-bib-0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"2026012114184841300_ehf213693-bib-0026","doi-asserted-by":"crossref","first-page":"16584","DOI":"10.1038\/s41598-019-53119-z","article-title":"Atrial fibrillation in the elderly: the role of sub-clinical isolated cardiac amyloidosis","volume":"9","author":"Krishnappa","year":"2019","journal-title":"Sci Rep"},{"key":"2026012114184841300_ehf213693-bib-0027","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0028","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ehf2.12884","article-title":"Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan","volume":"7","author":"Yamada","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"Suppl 1","key":"2026012114184841300_ehf213693-bib-0029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/13506129.2011.574354059","article-title":"Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy","volume":"18","author":"Connors","year":"2011","journal-title":"Amyloid"},{"key":"2026012114184841300_ehf213693-bib-0030","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0031","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ejhf.1563","article-title":"Real-world versus trial patients with transthyretin amyloid cardiomyopathy","volume":"21","author":"Canepa","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114184841300_ehf213693-bib-0032","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0033","article-title":"Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation","author":"Minutoli","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0034","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0035","volume-title":"ASNC cardiac amyloidosis practice points: 99mtechnetium-pyrophosphate imaging for transthyretin cardiac amyloidosis (version 2.0, updated February 2019)","author":"American Society of Nuclear Cardiology","year":"2021"},{"key":"2026012114184841300_ehf213693-bib-0036","article-title":"The evolving role of cardiovascular magnetic resonance imaging in the evaluation of systemic amyloidosis","volume":"12","author":"Banypersad","year":"2019","journal-title":"Magn Reson Insights"},{"key":"2026012114184841300_ehf213693-bib-0037","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0038","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"2026012114184841300_ehf213693-bib-0039","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0041","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1007\/s00330-017-4845-5","article-title":"Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy","volume":"27","author":"Oda","year":"2017","journal-title":"Eur Radiol"},{"key":"2026012114184841300_ehf213693-bib-0042","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1148\/radiol.2502080498","article-title":"Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment\u2014report of 33 cases","volume":"250","author":"Perez-Rodriguez","year":"2009","journal-title":"Radiology"},{"key":"2026012114184841300_ehf213693-bib-0043","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000289","article-title":"Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy","volume":"3","author":"Damy","year":"2016","journal-title":"Open Heart"},{"key":"2026012114184841300_ehf213693-bib-0044","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0045","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00259-018-4013-4","article-title":"Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis","volume":"45","author":"Treglia","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026012114184841300_ehf213693-bib-0046","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12350-018-1307-7","article-title":"Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis","volume":"27","author":"Einstein","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0047","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0048","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0049","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1536\/ihj.18-345","article-title":"Prevalence of positive 99 mTc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly","volume":"60","author":"Kim","year":"2019","journal-title":"Int Heart J"},{"key":"2026012114184841300_ehf213693-bib-0050","article-title":"Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation","author":"Cuscaden","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0051","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0052","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0053","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s12350-020-02205-1","article-title":"Tc-99m-pyrophosphate scintigraphy for the diagnosis of ATTR cardiac amyloidosis: comparison of quantitative and semi-quantitative approaches","volume":"27","author":"R\u00e9gis","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0054","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s12350-020-02094-4","article-title":"Cases from a busy nuclear cardiology laboratory: potential pitfalls in the interpretation of cardiac scintigraphy for ATTR cardiac amyloidosis","volume":"28","author":"Wehbe","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0055","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0056","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012114184841300_ehf213693-bib-0057","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1253\/circrep.CR-19-0015","article-title":"Utility of 99mTc-pyrophosphate scintigraphy in diagnosing transthyretin cardiac amyloidosis in real-world practice","volume":"1","author":"Tsutsui","year":"2019","journal-title":"Circ Rep"},{"key":"2026012114184841300_ehf213693-bib-0058","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012114184841300_ehf213693-bib-0059","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0060","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"2026012114184841300_ehf213693-bib-0061","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/13506129.2018.1493989","article-title":"Right ventricular involvement in transthyretin amyloidosis","volume":"25","author":"Arvidsson","year":"2018","journal-title":"Amyloid"},{"key":"2026012114184841300_ehf213693-bib-0062","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12203","article-title":"Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis","volume":"5","author":"Takashio","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2026012114184841300_ehf213693-bib-0063","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jjcc.2019.05.011","article-title":"Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy","volume":"75","author":"Ochi","year":"2020","journal-title":"J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0064","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.humpath.2010.11.017","article-title":"Wild-type transthyretin-derived amyloidosis in various ligaments and tendons","volume":"42","author":"Sueyoshi","year":"2011","journal-title":"Hum Pathol"},{"key":"2026012114184841300_ehf213693-bib-0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study","volume":"329","author":"Vianello","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0066","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1253\/circj.CJ-19-0255","article-title":"Combination of commonly examined parameters is a useful predictor of positive 99mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis","volume":"83","author":"Marume","year":"2019","journal-title":"Circ J"},{"key":"2026012114184841300_ehf213693-bib-0067","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jjcc.2020.06.019","article-title":"Validation of the Kumamoto criteria for prediction of 99mtechnetium pyrophosphate scintigraphy positivity as a strategy for diagnosis of transthyretin cardiac amyloidosis: a retrospective cohort study in Kochi","volume":"77","author":"Ochi","year":"2021","journal-title":"J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0068","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1253\/circj.CJ-19-0811","article-title":"A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Endo","year":"2019","journal-title":"Circ J"},{"key":"2026012114184841300_ehf213693-bib-0069","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/ehjci\/jeab095","article-title":"99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis","volume":"22","author":"Quarta","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0070","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s12350-020-02107-2","article-title":"Unusual high 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) tracer deposition on a heart scintigraphy in a patient with AL amyloidosis: a case report","volume":"28","author":"Persia-Paulino","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0071","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025582","article-title":"False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: case report","volume":"100","author":"Zeng","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 1","key":"2026012114184841300_ehf213693-bib-0072","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2017.1284060","article-title":"Myocardial uptake of 99mTc-DPD in patients with AL amyloidosis","volume":"24","author":"de Miguel","year":"2017","journal-title":"Amyloid"},{"key":"2026012114184841300_ehf213693-bib-0073","article-title":"Grade 3 myocardial uptake in 99mtechnetium-pyrophosphate scintigraphy in light chain cardiac amyloidosis","volume":"5","author":"Okada","year":"2021","journal-title":"Eur Heart J Case Rep"},{"key":"2026012114184841300_ehf213693-bib-0074","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007558","article-title":"False-positive 99mtechnetium-pyrophosphate scintigraphy in two patients with hypertrophic cardiomyopathy","volume":"14","author":"Schafer","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026012114184841300_ehf213693-bib-0075","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1002\/ehf2.13339","article-title":"False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy","volume":"8","author":"Chimenti","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114184841300_ehf213693-bib-0076","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.007059","article-title":"Hydroxychloroquine-mediated cardiotoxicity with a false-positive 99mtechnetium-labeled pyrophosphate scan for transthyretin-related cardiac amyloidosis","volume":"11","author":"Chang","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0077","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s13139-017-0486-5","article-title":"Altered biodistribution of 99mTc-DPD on bone scan after intravenous iron supplement","volume":"51","author":"Shin","year":"2017","journal-title":"Nucl Med Mol Imaging"},{"key":"2026012114184841300_ehf213693-bib-0078","article-title":"Tc-99m HMDP bone scintigraphy for cardiac amyloidosis diagnosis: a false positive case","author":"Lades","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0079","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2020.02.030","article-title":"Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis","volume":"307","author":"Grigoratos","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0080","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012114184841300_ehf213693-bib-0081","first-page":"50","article-title":"A case report of an uncommon presentation of 99mtechnetium pyrophosphate scintigraphy in transthyretin cardiac amyloidosis: a potential diagnostic pitfall, pseudo-positive or pseudo-negative?","volume":"21","author":"Ochi","year":"2020","journal-title":"J Cardiol Cases"},{"key":"2026012114184841300_ehf213693-bib-0082","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"2026012114184841300_ehf213693-bib-0083","doi-asserted-by":"crossref","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026012114184841300_ehf213693-bib-0084","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11886-017-0868-4","article-title":"Targeted nuclear imaging probes for cardiac amyloidosis","volume":"19","author":"Bravo","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"Suppl 1","key":"2026012114184841300_ehf213693-bib-0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13506129.2019.1583192","article-title":"Cost-effectiveness of technetium pyrophosphate scintigraphy versus heart biopsy for the diagnosis of transthyretin amyloidosis","volume":"26","author":"Ruiz-Negr\u00f3n","year":"2019","journal-title":"Amyloid"},{"key":"2026012114184841300_ehf213693-bib-0086","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord"}],"updated-by":[{"DOI":"10.1002\/ehf2.14007","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000}}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13693","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/251\/65375045\/eschf_9_1_251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/1\/251\/65375045\/eschf_9_1_251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:22:26Z","timestamp":1769023346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/1\/251\/8326395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13693","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,2]]},"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"2021-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}